Douwe Schulte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Douwe Schulte has a total of 137 co-authors. Here are the top co-authors by number of shared publications:
- Joost Snijder
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Department of Chemistry, Faculty of Science, Utrecht University, Utrecht, The Netherlands
16 shared publications - Albert J. R. Heck
Utrecht University Padualaan 8
9 shared publications - Weiwei Peng
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University
6 shared publications - Marta Šiborová
University of Copenhagen
4 shared publications - Matti Feije Pronker
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute of Pharmaceutical Sciences, Utrecht University
4 shared publications - Maurits A. Den Boer
Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of Utrecht
4 shared publications
Latest Publications
- Open Access
Reference-free protein sequencing by consensus assembly of redundant de novo peptide reads
Reading a protein's sequence from tandem mass spectra without a reference is limited by single-spectrum accuracy, most acutely across the hypervariable complementarity-determining regions of antibodies. Broadly specific proteases tile a protein with long, overlapping peptides, so every residue is covered by many independent de novo reads. borgonovo assembles their per-step probability profiles into a reference-free per-residue consensus, seeding templates from mass-closure-consistent reads and recruiting the rest by substitution-tolerant alignment and per-column voting. Re-decoding each spectrum with a prior from its consensus position lifts amino acid accuracy on placed spectra from 0.80 to 0.87. On the therapeutic antibody trastuzumab, nine proteases cover its heavy and light chains completely at 0.88 fixed-window identity and 0.93 on the pruned assembly once local indels are accommodated. Applied unchanged to five secretome proteins and trastuzumab with three proteases, it reaches 0.87 mean fixed-window identity over 82% coverage. borgonovo is open source and works with most de novo sequencers, so redundant digestion turns any of them into a protein sequencer where no reference exists.
Open AccessReference-free protein sequencing by consensus assembly of redundant de novo peptide reads
Reading a protein's sequence from tandem mass spectra without a reference is limited by single-spectrum accuracy, most acutely across the hypervariable complementarity-determining regions of antibodies. Broadly specific proteases tile a protein with long, overlapping peptides, so every residue is covered by many independent de novo reads. borgonovo assembles their per-step probability profiles into a reference-free per-residue consensus, seeding templates from mass-closure-consistent reads and recruiting the rest by substitution-tolerant alignment and per-column voting. Re-decoding each spectrum with a prior from its consensus position lifts amino acid accuracy on placed spectra from 0.80 to 0.87. On the therapeutic antibody trastuzumab, nine proteases cover its heavy and light chains completely at 0.88 fixed-window identity and 0.93 on the pruned assembly once local indels are accommodated. Applied unchanged to five secretome proteins and trastuzumab with three proteases, it reaches 0.87 mean fixed-window identity over 82% coverage. borgonovo is open source and works with most de novo sequencers, so redundant digestion turns any of them into a protein sequencer where no reference exists.
- Open Access
- 11 July 2026
- Published by Elsevier in Journal of Proteomics
- Vol. 331, 105708
Community-driven advances in computational mass spectrometry: The perspective of EuBIC-MS members
- 11 July 2026
- Published by Elsevier in Journal of Proteomics
- Vol. 331, 105708
Open AccessCommunity-driven advances in computational mass spectrometry: The perspective of EuBIC-MS members
- Open Access
Direct serological antibody discovery by integrative proteomics yields potent neutralizers overlooked by single-cell BCR sequencing
Human antibody discovery relies on accessing in vivo -matured repertoires, yet conventional single-cell B cell receptor sequencing (scBCR-seq) often overlooks the most relevant, functional antibodies secreted by plasma cells. Here, we introduce AbDirect, a protein-centric discovery platform that obtains antibody sequences directly from small-volume biofluids. In this proof-of-concept, we apply AbDirect to potent COVID-19 plasma from which an early-pandemic scBCR-seq study did not identify neutralizers. Upfront reactivity screening of anti-SARS-CoV-2 spike protein repertoires revealed diverse clonal profiles with distinct cross-reactivity and subunit specificity. Targeted de novo sequencing via standalone integrative proteomics yielded 14 IgG1 and 4 IgA1 clones that diverged markedly from peripheral B cell counterparts in germline usage and phylogeny, indicating distinct immunological compartments. Validation via recombinant mAbs demonstrated superior binding and highly potent neutralization for multiple sequenced clones (three with IC 50 ≤1.4 nM). AbDirect thus yielded potent antibodies overlooked by scBCR-seq, demonstrating serological discovery as a powerful complementary approach for uncovering functional repertoires that may be inaccessible to cell-based methods.
Open AccessDirect serological antibody discovery by integrative proteomics yields potent neutralizers overlooked by single-cell BCR sequencing
Human antibody discovery relies on accessing in vivo -matured repertoires, yet conventional single-cell B cell receptor sequencing (scBCR-seq) often overlooks the most relevant, functional antibodies secreted by plasma cells. Here, we introduce AbDirect, a protein-centric discovery platform that obtains antibody sequences directly from small-volume biofluids. In this proof-of-concept, we apply AbDirect to potent COVID-19 plasma from which an early-pandemic scBCR-seq study did not identify neutralizers. Upfront reactivity screening of anti-SARS-CoV-2 spike protein repertoires revealed diverse clonal profiles with distinct cross-reactivity and subunit specificity. Targeted de novo sequencing via standalone integrative proteomics yielded 14 IgG1 and 4 IgA1 clones that diverged markedly from peripheral B cell counterparts in germline usage and phylogeny, indicating distinct immunological compartments. Validation via recombinant mAbs demonstrated superior binding and highly potent neutralization for multiple sequenced clones (three with IC 50 ≤1.4 nM). AbDirect thus yielded potent antibodies overlooked by scBCR-seq, demonstrating serological discovery as a powerful complementary approach for uncovering functional repertoires that may be inaccessible to cell-based methods.
- 29 January 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (5) , 3544-3556
Spectral Quality-Guided Optimization of Hybrid EAciD Fragmentation on the ZenoTOF 7600 System Enables Efficient Characterization of the Serum N -Glycoproteome
The analysis of N-glycopeptides using mass spectrometry comes with numerous challenges, one of which is the unique fragmentation features associated with glycopeptides. Generally, low energy collision-based fragmentation can provide valuable information by the glycan-related B- and Y-ions but often at the expense of peptide backbone coverage. On the other hand, while electron-based fragmentation methods provide good peptide backbone coverage and allow glycan localization, they do not generate sufficient structural details on the glycans by missing B- and Y-ions. Here, we systematically optimized a ZenoTOF 7600 system employing electron-activated dissociation (EAD) as an alternative electron-based fragmentation method. Combined with collision-induced dissociation (CID), hybrid fragmentation (EAciD) on N-glycopeptides generated information-rich MS2 spectra that improved the identification of N-glycopeptides in complex samples. We applied this method to a small cohort of blood donors, analyzing glycopeptide-enriched blood samples of healthy donors and patients suffering from pancreatic cancer or hepatocellular carcinoma. On the ZenoTOF 7600 system, we were able to efficiently detect ∼1900 glycopeptides per sample. EAciD especially performed well in sequencing and identifying very large N-glycopeptides carrying sizable and structurally complex glycan moieties. This allowed us to observe disease-specific N-glycopeptide signatures on numerous highly abundant blood proteins, mostly related to changes in fucosylation and complex extended glycoforms.
- 29 January 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (5) , 3544-3556
Spectral Quality-Guided Optimization of Hybrid EAciD Fragmentation on the ZenoTOF 7600 System Enables Efficient Characterization of the Serum N -Glycoproteome
The analysis of N-glycopeptides using mass spectrometry comes with numerous challenges, one of which is the unique fragmentation features associated with glycopeptides. Generally, low energy collision-based fragmentation can provide valuable information by the glycan-related B- and Y-ions but often at the expense of peptide backbone coverage. On the other hand, while electron-based fragmentation methods provide good peptide backbone coverage and allow glycan localization, they do not generate sufficient structural details on the glycans by missing B- and Y-ions. Here, we systematically optimized a ZenoTOF 7600 system employing electron-activated dissociation (EAD) as an alternative electron-based fragmentation method. Combined with collision-induced dissociation (CID), hybrid fragmentation (EAciD) on N-glycopeptides generated information-rich MS2 spectra that improved the identification of N-glycopeptides in complex samples. We applied this method to a small cohort of blood donors, analyzing glycopeptide-enriched blood samples of healthy donors and patients suffering from pancreatic cancer or hepatocellular carcinoma. On the ZenoTOF 7600 system, we were able to efficiently detect ∼1900 glycopeptides per sample. EAciD especially performed well in sequencing and identifying very large N-glycopeptides carrying sizable and structurally complex glycan moieties. This allowed us to observe disease-specific N-glycopeptide signatures on numerous highly abundant blood proteins, mostly related to changes in fucosylation and complex extended glycoforms.
- Open Access
- 14 October 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (42) , 23120-23130
A Universal Spectrum Annotator for Complex Peptidoforms in Mass Spectrometry-Based Proteomics
Accurate and comprehensive peptide spectrum annotation is a crucial step to interpreting mass spectrometry-based proteomics data. While peak assignment in peptide fragmentation spectra is central to a broad range of proteomics applications, current tools tend to be specialized to a specific task. Here, we present a more comprehensive interactive graphical tool (Annotator), along with the underlying codebase written in Rust (rustyms). Annotator enables unified spectrum annotation for bottom-up, middle-down, top-down, cross-linked, and glycopeptide fragmentation mass spectra from all fragmentation methods, including all ion types: a/b/c, x/y/z, d/v/w, and immonium ions. The Annotator integrates all known post-translational modifications from common databases and additionally allows for the definition of custom fragmentation models and modifications. Modifications allow for diagnostic fragment ions, site-specific neutral losses, and multiple breakage sites for cross-linkers. The underlying library used for the theoretical fragmentation and matching is based on the unified peptidoform notation ProForma 2.0 and is made available as a Rust library with Python bindings. This enables spectrum annotation in an interactive, graphical interface of diverse and complex peptidoforms across the broad range of mass spectrometry-based proteomics applications.
- 14 October 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (42) , 23120-23130
Open AccessA Universal Spectrum Annotator for Complex Peptidoforms in Mass Spectrometry-Based Proteomics
Accurate and comprehensive peptide spectrum annotation is a crucial step to interpreting mass spectrometry-based proteomics data. While peak assignment in peptide fragmentation spectra is central to a broad range of proteomics applications, current tools tend to be specialized to a specific task. Here, we present a more comprehensive interactive graphical tool (Annotator), along with the underlying codebase written in Rust (rustyms). Annotator enables unified spectrum annotation for bottom-up, middle-down, top-down, cross-linked, and glycopeptide fragmentation mass spectra from all fragmentation methods, including all ion types: a/b/c, x/y/z, d/v/w, and immonium ions. The Annotator integrates all known post-translational modifications from common databases and additionally allows for the definition of custom fragmentation models and modifications. Modifications allow for diagnostic fragment ions, site-specific neutral losses, and multiple breakage sites for cross-linkers. The underlying library used for the theoretical fragmentation and matching is based on the unified peptidoform notation ProForma 2.0 and is made available as a Rust library with Python bindings. This enables spectrum annotation in an interactive, graphical interface of diverse and complex peptidoforms across the broad range of mass spectrometry-based proteomics applications.
- Open Access
- 22 July 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (8) , 2357-2366
Structural Basis for Postfusion-Specific Binding to the Respiratory Syncytial Virus F Protein by the Canonical Antigenic Site I Antibody 131–2a
The respiratory syncytial virus (RSV) fusion (F) protein is a major target of antiviral antibodies following natural infection or vaccination and is responsible for mediating fusion between the viral envelope and the host membrane. The fusion process is driven by a large-scale conformational change in F, switching irreversibly from the metastable prefusion state to the stable postfusion conformation. Previous research has identified six distinct antigenic sites in RSV-F, termed sites Ø, I, II, III, IV, and V. Of these, only antigenic site I is fully specific to the postfusion conformation of F. A monoclonal antibody 131-2a that specifically targets postfusion F has been widely used as a research tool to probe for postfusion F and to define antigenic site I in serological studies, yet its sequence and precise epitope have remained unknown. Here, we use mass spectrometry-based de novo sequencing of 131-2a to reverse engineer a recombinant product and study the epitope to define antigenic site I with molecular detail, revealing the structural basis for the antibody's specificity toward postfusion RSV-F.
- 22 July 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 11 (8) , 2357-2366
Open AccessStructural Basis for Postfusion-Specific Binding to the Respiratory Syncytial Virus F Protein by the Canonical Antigenic Site I Antibody 131–2a
The respiratory syncytial virus (RSV) fusion (F) protein is a major target of antiviral antibodies following natural infection or vaccination and is responsible for mediating fusion between the viral envelope and the host membrane. The fusion process is driven by a large-scale conformational change in F, switching irreversibly from the metastable prefusion state to the stable postfusion conformation. Previous research has identified six distinct antigenic sites in RSV-F, termed sites Ø, I, II, III, IV, and V. Of these, only antigenic site I is fully specific to the postfusion conformation of F. A monoclonal antibody 131-2a that specifically targets postfusion F has been widely used as a research tool to probe for postfusion F and to define antigenic site I in serological studies, yet its sequence and precise epitope have remained unknown. Here, we use mass spectrometry-based de novo sequencing of 131-2a to reverse engineer a recombinant product and study the epitope to define antigenic site I with molecular detail, revealing the structural basis for the antibody's specificity toward postfusion RSV-F.
- Open Access
- 18 March 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 14
Simultaneous polyclonal antibody sequencing and epitope mapping by cryo electron microscopy and mass spectrometry – a perspective
Antibodies are a major component of adaptive immunity against invading pathogens. Here we explore possibilities for an analytical approach to characterize the antigen-specific antibody repertoire directly from the secreted proteins in convalescent serum. This approach aims to perform simultaneous antibody sequencing and epitope mapping using a combination of single particle cryo-electron microscopy (cryoEM) and bottom-up proteomics techniques based on mass spectrometry (LC-MS/MS). We evaluate the performance of the deep-learning tool ModelAngelo in determining de novo antibody sequences directly from reconstructed 3D volumes of antibody-antigen complexes. We demonstrate that while map quality is a critical bottleneck, it is possible to sequence antibody variable domains from cryoEM reconstructions with accuracies of up to 80-90%. While the rate of errors exceeds the typical levels of somatic hypermutation, we show that the ModelAngelo-derived sequences can be used to assign the used V-genes. This provides a functional guide to assemble de novo peptides from LC-MS/MS data more accurately and improves the tolerance to a background of polyclonal antibody sequences. Following this proof-of-principle, we discuss the feasibility and future directions of this approach to characterize antigen-specific antibody repertoires.
- 18 March 2025
- Published by eLife Sciences Publications, Ltd in eLife preprints
- Vol. 14
Open AccessSimultaneous polyclonal antibody sequencing and epitope mapping by cryo electron microscopy and mass spectrometry – a perspective
Antibodies are a major component of adaptive immunity against invading pathogens. Here we explore possibilities for an analytical approach to characterize the antigen-specific antibody repertoire directly from the secreted proteins in convalescent serum. This approach aims to perform simultaneous antibody sequencing and epitope mapping using a combination of single particle cryo-electron microscopy (cryoEM) and bottom-up proteomics techniques based on mass spectrometry (LC-MS/MS). We evaluate the performance of the deep-learning tool ModelAngelo in determining de novo antibody sequences directly from reconstructed 3D volumes of antibody-antigen complexes. We demonstrate that while map quality is a critical bottleneck, it is possible to sequence antibody variable domains from cryoEM reconstructions with accuracies of up to 80-90%. While the rate of errors exceeds the typical levels of somatic hypermutation, we show that the ModelAngelo-derived sequences can be used to assign the used V-genes. This provides a functional guide to assemble de novo peptides from LC-MS/MS data more accurately and improves the tolerance to a background of polyclonal antibody sequences. Following this proof-of-principle, we discuss the feasibility and future directions of this approach to characterize antigen-specific antibody repertoires.
- Open Access
- 13 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
In-depth plasma N-glycoproteome profiling using narrow-window data-independent acquisition on the Orbitrap Astral mass spectrometer
Recently, a conceptually new mass analyzer was introduced by pairing a quadrupole Orbitrap mass spectrometer with an asymmetric track lossless (Astral™) analyzer. This system provides >200 Hz MS/MS scanning speed, high resolving power, sensitivity, and mass accuracy. Due to its speed, the instrument allows for a narrow-window data-independent acquisition (nDIA) strategy, representing a new technical milestone in peptide-centric proteomics. However, this new system may also be applied to other complex and clinically important proteomes, such as the human plasma N-glycoproteome. Here, we evaluate the Orbitrap Astral mass spectrometer for the in-depth analysis of the plasma N-glycoproteome and pioneer a dedicated nDIA workflow, termed “nGlycoDIA”, on glycopeptide enriched and crude plasma. This strategy leads to the cumulative identification of over 3000 unique glycoPSMs derived from 181 glycoproteins in just 40 minutes and covers a dynamic range of 7 orders of magnitude for a glycopeptide enriched plasma sample. Notably, we detect several glycosylated cytokines that have reported plasma concentrations in the ng/L range. Furthermore, shortening the gradient to 10 min still allows for the detection of almost 1850 (95% CI [1840-1860]) unique glycoPSMs, indicating that high-throughput in-depth clinical plasma glycoproteomics may be within reach.
- 13 March 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessIn-depth plasma N-glycoproteome profiling using narrow-window data-independent acquisition on the Orbitrap Astral mass spectrometer
Recently, a conceptually new mass analyzer was introduced by pairing a quadrupole Orbitrap mass spectrometer with an asymmetric track lossless (Astral™) analyzer. This system provides >200 Hz MS/MS scanning speed, high resolving power, sensitivity, and mass accuracy. Due to its speed, the instrument allows for a narrow-window data-independent acquisition (nDIA) strategy, representing a new technical milestone in peptide-centric proteomics. However, this new system may also be applied to other complex and clinically important proteomes, such as the human plasma N-glycoproteome. Here, we evaluate the Orbitrap Astral mass spectrometer for the in-depth analysis of the plasma N-glycoproteome and pioneer a dedicated nDIA workflow, termed “nGlycoDIA”, on glycopeptide enriched and crude plasma. This strategy leads to the cumulative identification of over 3000 unique glycoPSMs derived from 181 glycoproteins in just 40 minutes and covers a dynamic range of 7 orders of magnitude for a glycopeptide enriched plasma sample. Notably, we detect several glycosylated cytokines that have reported plasma concentrations in the ng/L range. Furthermore, shortening the gradient to 10 min still allows for the detection of almost 1850 (95% CI [1840-1860]) unique glycoPSMs, indicating that high-throughput in-depth clinical plasma glycoproteomics may be within reach.
- Open Access
A universal spectrum annotator for complex peptidoforms in mass spectrometry-based proteomics
Accurate and comprehensive peptide spectrum annotation is a crucial step to interpret mass spectrometry-based proteomics data. While peak assignment in peptide fragmentation spectra is central to a broad range of proteomics applications, current tools tend to be specialized to a specific task. Here we present a more comprehensive tool, the Annotator, which unifies spectrum annotation for bottom-up, middle-down, top-down, cross-linked, and glycopeptide fragmentation mass spectra, from all fragmentation methods, including all ion types: a/b/c, x/y/z, d/v/w, and immonium ions. The Annotator integrates all known post-translational modifications from common databases and additionally allows for the definition of custom fragmentation models and modifications. Modifications allow for diagnostic fragment ions, site specific neutral losses, and multiple breakage sites for cross-linkers. The underlying library used for the theoretical fragmentation and matching is based on the unified peptidoform notation ProForma 2.0 and made available as a Rust library (rustyms) with Python bindings. This enables spectrum annotation of diverse and complex peptidoforms across the broad range of mass spectrometry-based proteomics applications.
Open AccessA universal spectrum annotator for complex peptidoforms in mass spectrometry-based proteomics
Accurate and comprehensive peptide spectrum annotation is a crucial step to interpret mass spectrometry-based proteomics data. While peak assignment in peptide fragmentation spectra is central to a broad range of proteomics applications, current tools tend to be specialized to a specific task. Here we present a more comprehensive tool, the Annotator, which unifies spectrum annotation for bottom-up, middle-down, top-down, cross-linked, and glycopeptide fragmentation mass spectra, from all fragmentation methods, including all ion types: a/b/c, x/y/z, d/v/w, and immonium ions. The Annotator integrates all known post-translational modifications from common databases and additionally allows for the definition of custom fragmentation models and modifications. Modifications allow for diagnostic fragment ions, site specific neutral losses, and multiple breakage sites for cross-linkers. The underlying library used for the theoretical fragmentation and matching is based on the unified peptidoform notation ProForma 2.0 and made available as a Rust library (rustyms) with Python bindings. This enables spectrum annotation of diverse and complex peptidoforms across the broad range of mass spectrometry-based proteomics applications.
- Open Access
Structural basis for postfusion-specific binding to Respiratory Syncytial Virus F protein by the canonical antigenic site I antibody 131-2a
The Respiratory Syncytial Virus (RSV) Fusion (F) protein is a major target of antiviral antibodies following natural infection or vaccination and responsible for mediating fusion between the viral envelope and the host membrane. The fusion process is driven by a large-scale conformational change in F, switching irreversibly from the metastable prefusion state to the stable postfusion conformation. Previous research has identified six distinct antigenic sites in RSV-F, termed sites Ø, I, II, III, IV, and V. Of these, only antigenic site I is fully specific to the postfusion conformation of F. A monoclonal antibody 131-2a that specifically targets postfusion F has been widely used as a research tool to probe for postfusion F and to define antigenic site I in serological studies, yet its sequence and precise epitope have remained unknown. Here we use mass spectrometry-based de novo sequencing of 131-2a to reverse engineer a recombinant product and study the epitope to define antigenic site I with molecular detail, revealing the structural basis for the antibody’s specificity towards postfusion RSV-F.
Open AccessStructural basis for postfusion-specific binding to Respiratory Syncytial Virus F protein by the canonical antigenic site I antibody 131-2a
The Respiratory Syncytial Virus (RSV) Fusion (F) protein is a major target of antiviral antibodies following natural infection or vaccination and responsible for mediating fusion between the viral envelope and the host membrane. The fusion process is driven by a large-scale conformational change in F, switching irreversibly from the metastable prefusion state to the stable postfusion conformation. Previous research has identified six distinct antigenic sites in RSV-F, termed sites Ø, I, II, III, IV, and V. Of these, only antigenic site I is fully specific to the postfusion conformation of F. A monoclonal antibody 131-2a that specifically targets postfusion F has been widely used as a research tool to probe for postfusion F and to define antigenic site I in serological studies, yet its sequence and precise epitope have remained unknown. Here we use mass spectrometry-based de novo sequencing of 131-2a to reverse engineer a recombinant product and study the epitope to define antigenic site I with molecular detail, revealing the structural basis for the antibody’s specificity towards postfusion RSV-F.